LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

Patient Characteristics

Study 19 included BRCAm patients from various age groups and ECOG§§ performance status levels.3

BRCam patients from various age groups
BRCam patients from various age groups

Adapted with permission from Ledermann.3  

*ECOG: Eastern Cooperative Oncology Group.

§§Ancestry was self-reported.

  • Eligible patients were aged 18 years or older and had recurrent ovarian or fallopian tube cancer, or primary peritoneal cancer, with high-grade (grade 2 or 3) serous features or a serous component, which was platinum-sensitive (defined as no disease progression in the first 6 months after the last dose of the penultimate line of platinum-based chemotherapy).2
  • Patients entering the study had received two or more previous courses of platinum-based chemotherapy and were required to have shown an objective response (complete or partial response) according to Response Evaluation Criteria In Solid Tumors (RECIST) or Gynaecologic Cancer Intergroup criteria.2
Objective response to most recent platinum-based regimen
Objective response to most recent platinum-based regimen

Adapted with permission from Ledermann.3